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Background: Cognitive impairment is not only a core aspect of schizophrenia but also 
commonly observed in help-seeking youth at ultra high risk for psychosis (UHR), with 
potential implications for prognosis and individualized treatment. However, there is no 
consensus on the cognitive profile in the UHR state, partly due to lack of valid comparisons 
of performance in established schizophrenia and UHR.
Objectives: To compare the cognitive functioning and profile of UHR subjects to a 
sample with schizophrenia, they were split into two groups based on duration of illness. 
Comparisons were made using coordinated norms based on healthy controls reflecting 
the younger UHR age spectrum.
Methods: Participants for UHR (n = 51) and schizophrenia groups (n = 19 and n = 
22) were included from the Prevention of Psychosis and Bergen Psychosis 2 projects. 
All subjects completed a comprehensive neurocognitive test battery aiming to measure 
speed of processing, working memory, verbal learning, reasoning, and problem solving, 
as well as visual problem solving. Cognitive functioning was compared between groups 
based on coordinated norms using z-scores derived by regression modeling from an age-
matched healthy control group (n = 61).
Results: UHR subjects showed significantly impaired speed of processing (p < 0.001) working 
memory (p = 0.042) and verbal learning, reasoning, and problem solving (p = 0.007) as compared 
to the control group. Visual problem-solving skills appeared unimpaired. UHR subjects 
significantly outperformed the schizophrenia group with duration of illness >3 years for speed 
of processing and working memory (both p < 0.001). There were no significant differences in 
performance between the UHR group and the group with duration of schizophrenia <3 years.
Conclusion: Cognitive performance is impaired in UHR subjects as compared to healthy 
controls and should thus be monitored when a person is deemed at high risk of psychotic 
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INTRODUCTION
Cognitive impairment is a core characteristic of schizophrenia (1). 
The majority of patients with schizophrenia fall below the cognitive 
performance level expected according to premorbid functioning 
or parental educational levels (2). Cognitive impairment likely 
precedes the appearance of overt psychotic symptoms, and some 
authors suggest that it is a neurobiological marker for psychosis 
risk (3). Impairment in episodic and working memory, 
speed of processing, verbal fluency, attention, and executive 
functions have robustly been demonstrated (4). Impairment 
in cognitive functioning is associated with a higher likelihood 
of relapse (5), poor functional outcome (6), and worse quality 
of life (7) and is thus an important prognostic indicator in 
clinical settings.
If cognitive decline starts in the prodromal phase of 
schizophrenia (3), it could be hypothesized that cognitive 
impairment also presents a challenge for help-seeking young 
people at ultra high risk for psychosis (UHR). Cognitive 
impairment in UHR could affect both social and academic 
functioning as well as the ability to profit from psychosocial 
therapy and interventions, which are often the first choice for 
this patient group (8). Managing or ameliorating cognitive 
dysfunction in psychotic disorders is therefore central to clinical 
recovery and to helping people function in the community. In 
addition, understanding how UHR cognitive changes compare to 
those seen in full-blown psychosis may further the understanding 
of etiology and course in psychotic disorders.
Cognitive Impairment in the  
Psychosis Continuum
The continuum model of psychosis sees the psychosis spectrum 
as ranging from mild attenuated experiences in many otherwise 
healthy individuals, to clinically significant and severe symptoms 
in a few who fulfill diagnostic criteria for psychotic disorders 
(9). The UHR state falls into the milder end of this continuum, 
while schizophrenia is considered to be the most severe form in 
terms of symptom load and duration (10). In accordance with 
this, cognitive impairment in UHR appears to be milder than 
in schizophrenia. Furthermore, impairment in first-episode 
psychosis has been found to be less severe than in chronic 
schizophrenia (11). Alongside studies showing slightly greater 
impairment in persons with a longer duration of untreated 
psychosis, this might suggest that abnormal neurodevelopmental 
processes happen prodromally and continue after the onset of 
psychosis (12).
A meta-analysis found 20% (confidence interval, 17–25%) 
of UHR patients to develop full-blown psychosis (13, 14). UHR 
individuals often seek help because psychosis-related symptoms 
and signs cause functional decline and reduced quality of life. 
Although up to 65% of UHR subjects clinically recover from 
attenuated psychosis symptoms within 2 years (15), they often 
continue to report other mental health problems, which require 
targeted intervention (16). Early intervention services aimed at 
reducing the duration of untreated psychotic symptoms may thus 
improve outcome in those at risk for psychosis (17) regardless of 
conversion status by paving the way for tailored support.
Understanding the cognitive profile of UHR as compared 
to general population controls and patients with schizophrenia 
may improve service delivery and individualized treatment and 
prognosis prediction for this group, potentially preventing psychosis 
conversion in some cases. Cognitive changes seem to predict 
conversion to psychosis in UHR individuals, with longitudinal 
studies indicating worsening cognitive functioning as an early sign 
of eventual full-blown psychosis (18). Distractibility has also been 
shown to predict the UHR marker of voice hearing in adolescents 
(19), indicating an association between cognitive functioning and 
psychosis symptoms.
Cognitive screening may contribute meaningfully to efforts 
to individualize early intervention services aimed at supporting 
UHR youth. Cognitive remediation training may improve 
cognitive functioning (20) and has few, if any, negative side 
effects, making it appropriate for UHR groups (21). Although 
the effect on symptom load appears to be marginal (22), 
improved cognition might improve function (23). Handling 
cognitive challenges is therefore important both for UHR 
patients who develop full-blown psychosis and to the large 
subgroup whose attenuated symptoms do not worsen, but 
for whom impaired cognitive functioning may still remain a 
problem (24). However, we cannot successfully provide this 
without more detailed knowledge about the nature of the 
cognitive challenges of this group.
UHR Groups and Cognitive Changes  
in Psychosis
It has been suggested that cognitive performance in UHR 
groups lie somewhere in between that of healthy controls 
and established psychotic illness (25). However, there is no 
clear consensus on the trajectory of cognitive changes ahead 
of and during psychotic illness. Subjects who later transit to 
psychosis have been found to show greater deficits than those 
who do not, albeit with modest effect sizes (26–28). These 
differences are not merely due to general cognitive ability 
(27). While some have argued that cognition declines across 
the course of psychotic illness (29), others have found no 
evidence of cognitive decline in patients with UHR, noting 
illness. Spatial skills, as measured by tests using physical objects, appear less affected 
than other domains. The pattern of impairment is similar to that of a group with recent 
onset schizophrenia but is less severe than in a group with duration of illness <3 years.
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that cognitive performances improve at follow-up (28). Our 
own research group similarly found significant cognitive 
improvement across the acute phase of psychosis (30). A 
recent 24-month longitudinal study of young people with 
early onset schizophrenia also found this group to have a 
similar cognitive course to healthy controls, albeit functioning 
at an overall lower level (31). Improvement has also been 
seen in first episode schizophrenia, even with test batteries 
designed to withstand learning effects (32). The only study 
to date to retest UHR subjects after 10 years found no decline 
in cognition except in tests of immediate verbal learning and 
memory (33). This study also found cognitive change over the 
decade not to be related to baseline IQ, symptomatic change, 
or transition status.
There is a similar lack of consensus on changes in the UHR 
phase in relation to individual cognitive domains. In their 
2014 meta-analysis, Bora et al. found the greatest impairment 
across UHR groups in symbol coding tests and more general 
measures of visuospatial working memory (28). A meta-
analysis by Fusar-Poli, Deste (26), however, found significantly 
lower general intelligence in subjects deemed at high risk of 
psychosis, with verbal and visual memory most impaired. They 
found no group differences in overall speed of processing, 
although also they noted that the digit-symbol coding task 
was the single test showing the biggest discrepancy between 
high-risk subjects and healthy controls. The notable variability 
in previous findings may be partly due to measurement 
discrepancies across studies. In addition, a variety of test 
batteries have been used. The UHR group is also clinically 
and demographically diverse. Getting a representative sample 
may be affected, e.g., by restricted access to early intervention 
services or mental health care in the area of recruitment. 
Comparing data from UHR groups to those from groups with 
psychosis also remains difficult due to the young age of the 
UHR population, which means that coordinated norms do not 
exist for many commonly used tests of cognitive functioning.
We designed the present study aiming to overcome challenges 
associated with young subject age using norms based on 
regression analyses of a control group sample, in order to 
allow for comparison with younger subjects across tests while 
adjusting for age and sex, thus enabling a comparison of cognitive 
profiles in UHR and schizophrenia. We also included both 
UHR subjects and two comparison schizophrenia groups from 
similar catchment areas, with universal access to free health care 
and well-structured clinical practices for early intervention in 
psychosis, as we aimed to get a more representative view of UHR 
cognitive performance than would be allowed when recruiting in 
a more restricted public health care system.
Aims and Hypotheses
The aim of the current paper is to examine the nature of cognitive 
dysfunction in UHR at the time of help seeking. UHR sample 
performance will be compared to performance in two groups 
with schizophrenia: one with recent onset of illness and one with 
longer duration of schizophrenia. Comparisons will be based 
on norms derived from healthy controls reflecting the younger 
age spectrum. These comparison groups will also allow us to use 
cognitive performance to illuminate the continuum model of 
psychotic illness.
We hypothesize the UHR group performance to fall below 
that of the healthy controls but above that of the schizophrenia 
groups. A secondary hypothesis is that the performance of 
recent onset schizophrenia participants will fall between the 
performance of the UHR group and the group with longer 
duration of illness. Given that measures of working memory 
and processing speed are found to be significantly impaired 
across studies, we hypothesize that impairment especially will be 
evident in demanding tasks loading on these cognitive functions, 
with our tests specifically designed to explore this.
METHODS
Study Design
UHR subjects were included from the Prevention of Psychosis 
Project (POP), an early intervention and treatment study 
encouraging at-risk individuals through information campaigns 
to seek relevant and early professional support. Rolling inclusion 
of POP participants took place from March 2012 to December 
2019 in health-care regions Stavanger and Fonna in Norway, 
with subjects assessed by low-threshold detection teams. POP 
offered participants a multimodal treatment program, adding 
antipsychotic medication at imminent risk of conversion only. 
The project aimed to significantly reduce the proportion of high-
risk subjects whom convert to psychosis in the catchment areas 
and has been described in detail elsewhere (34). Participants in 
the current substudy were recruited between 2012 and 2016.
Schizophrenia subjects were drawn from the Bergen Psychosis 
Project 2 (BP2). BP2 consists of a pharmaceutical-industry-
independent international and multisite pragmatic, randomized-
controlled trial (RCT) comparing three antipsychotics (amisulpride, 
aripiprazole, and olanzapine) for effects and side effects, with the 
aim of improving the specificity of antipsychotic treatment. An 
observational cohort of patients with psychosis not eligible for 
the RCT was included for comparison. All participants were 
followed up for 12 months. Participants in the current substudy 
were recruited between 2013 and 2016 from hospital sites in 
Bergen, Stavanger, and Trondheim in Norway, as well as from 
Innsbruck, Austria.
Participants
UHR Subjects (N = 52)
Inclusion criteria for participants drawn from the POP project 
were age 13–65 years and meeting diagnostic criteria for 
prodromal syndrome according to the Structured Interview For 
Prodromal Syndromes (SIPS) (35). The SIPS describes three 
different ways of fulfilling prodromal syndrome criteria. These 
are as follows: (1) brief intermittent psychotic syndrome (BIPS) 
as defined by experience of frank psychotic symptoms scoring 
at least 6 on the SOPS scale at least once per month but only 
in the last 3 months. brief intermittent psychotic syndrome is 
separated from current psychotic disorder by frequency and 
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duration/urgency. (2) Attenuated positive symptoms syndrome, 
meaning recent experience of attenuated positive symptoms 
scored to 3–5 on the scales P1–P5 of SOPS, starting or 
worsening in the past 12 months and occurring at least once per 
month. (3) Genetic risk and deterioration syndrome, defined by 
a combined first-degree family history of nonaffective psychotic 
disorder and a 30% or greater estimated drop in function as 
measured by Global Assessment of Functioning score over the 
past 12 months. In addition to meeting prodromal syndromes 
criteria, participants were also required to have IQ ≥ 70, ability 
to understand and speak Norwegian, and ability to understand 
and sign an informed consent or assent for minors’ document. 
Exclusion criteria were any current or lifetime psychotic 
disorder, if symptoms were better accounted for by an axis 
I, axis II, or substance use disorder, with the exception of 
schizotypal personality disorder, lifetime use of antipsychotic 
medication exceeding 4 weeks, or any known neurological 
or endocrine disorders that may have caused the presented 
psychotic symptoms. They were also required to not be using 
nor having used any antipsychotic medication (regardless of 
dosage) for more than 4 weeks lifetime.
Subjects With Schizophrenia (N = 48)
Subjects were included from the BP2 project if they had 
completed the comprehensive neuropsychological assessment 
forming part of their 3-month follow-up. Inclusion criteria 
for the RCT part of the BP2 were age >18, active psychosis 
as determined by a score ≥4 on either of the Positive and 
Negative Symptoms Scale (PANSS) interview (36) items for 
delusions (P1), hallucinatory behavior (P3), grandiosity (P5), 
suspiciousness/persecution (P6), or unusual thought content 
(G9); no known neurological or endocrine disorders likely to 
have caused the presented psychotic symptoms and the ability 
to understand and speak the site native language (in Norway 
or Austria). Inclusion criteria for the observational cohort part 
of the BP2 were age >16 and previous or current psychosis. 
Diagnoses were determined by the Structured Clinical 
Interview for the DSM-IV Axis I Disorders (SCID I) (37), 
with the following ICD-10 disorders eligible for participation 
in the BP2 study: schizophrenia (F20), schizotypal disorder 
(F21), delusional disorder (F22), acute psychotic disorders 
(F23), schizoaffective disorder (F25), other organic psychotic 
disorders (F28), and unspecified nonorganic psychosis (F29). 
The current sub-study only included BP2 participants fulfilling 
criteria for F20 schizophrenia to ensure a more homogenous 
comparison group in relation to cognitive performance.
Healthy Control Subjects (N = 61)
Healthy controls were recruited at the Stavanger site as part 
of both POP and BP2 projects. They were recruited among 
Stavanger University Hospital employees and their networks, 
high schools in the local area and posters in social security offices 
(NAV), aiming to gender and age match UHR participants and 
cover the age range of both UHR and psychosis participant 
groups. Participants with a known first-degree family history of 
psychiatric disorder or current or past drug dependence (other 
than nicotine products) were excluded from participating. All 
healthy controls received a small payment to cover travel costs 
and time.
Symptom and Functional Level Measures
UHR group baseline symptom load was measured by the SIPS 
interview (35). BP2 participants completed a PANSS assessment 
at baseline. A Structured Clinical Interview for the DSM-IV 
Axis I Disorders interview was administered to both groups 
by trained clinicians in order to determine diagnoses, with 
detailed results displayed in Table 1. Functioning was measured 
for all participants by the Global Assessment of Functioning, 
split version (38). All UHR subjects were antipsychotic naive (as 
per inclusion criteria) at the time of testing. Antipsychotic drug 
use in the schizophrenia group with psychosis was converted to 
defined daily doses (DDD), with DDD defined as “the assumed 
average maintenance dose per day for a drug used for its main 
indication in adults” (39). The control group completed PQ21 
as well as a MINI assessment in order to exclude any subjects 
with subthreshold psychotic symptoms or other mental illness. 
However, no control group participant was excluded due to this.
UHR subjects also completed a Norwegian version of the 
Premorbid Adjustment Scale (PAS) (40), a structured interview 
aiming to retrospectively assess social and academic premorbid 
adjustment. PAS yields five subscales used in the present study: 
Sociability and Withdrawal, Peer Relationships, Academic 
Achievement, Adaptation to School and Ability to Form 
Interpersonal and Sexual Relationships, each assessed for 
childhood (11 and younger), early and late adolescence (12–
15 and 16–18 years), and adulthood (19 and older). For the 
purposes of simplified reporting, a mean social adjustment 
score was calculated by averaging the scores of Sociability and 
Withdrawal and Peer Relationships for each stage.
Cognitive Measures
A comprehensive neurocognitive test battery was administered 
to POP project UHR participants at baseline and to BP2 
participants and healthy controls at their 3-month follow-up. 
The battery was designed to assess verbal functioning, visuo-
spatial functioning, and executive functions. Tests included in 
the present study were Trail Making A (TMA) and Trail Making 
B (TMB) (41), the California Verbal Learning test (42), Wechsler 
Adult Intelligence Scale III tests for number span, letter number 
sequencing, vocabulary, and block design (WMS) (43), WMS 
spatial span (44), as well as Delis–Kaplan Executive Function 
System (D-KEFS) Color Word Interference Test (CWIT), and 
FAS verbal fluency tests (45). Trained staff administered all 
neurocognitive testing.
Statistical Analysis
All analyses were performed using the Statistical Package for the 
Social Sciences 25.0.
Calculation of Coordinated Norms
Neuropsychological score variables were assessed for normality 
by way of creating histograms for inspection, both overall and 
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within groups. We standardized test raw scores by calculating 
z values relative to the baseline performance of our group of 
healthy controls. Calculation of z-scores was done to allow for 
comparisons across domains and tests and also because the 
young age of the UHR group in particular meant that valid test 
norms do not exist. This was done by running linear regression 
analyses for each variable, using age and gender as predictor 
variables. Based on the results from these we calculated 
expected scores adjusted for age and gender for each subject. 
Individual subject z-scores were then calculated by subtracting 
the expected score from the observed score in each variable and 
then dividing by the standard deviation of the control group. 
For tests where a higher raw score indicates worse performance 
(TMA, TMB, and CWIT), z-scores were inverted before further 
analyses. All negative z-scores thus indicate performance below 
that of controls.
Calculation of Cognitive Profile
For the purposes of the current study, test results were selected and 
grouped into cognitive domains according to existing literature and 
neuropsychological conventions (46). The cognitive domains used 
for the purposes of this study were speed of processing (TMA, WAIS 
digit symbol coding, CWIT color and word reading conditions), 
working memory (TMB, WAIS number span and letter number 
sequencing, inhibition, and inhibition and switching conditions from 
D-KEFS CWIT), verbal learning, reasoning, and problem solving 
TABLE 1 | Demographic variables and baseline cognitive test scores by group.
UHR
(n = 51)
Schizophrenia duration <3 
years (n = 19)
Schizophrenia duration <3 
years (n = 22)
Controls
(n = 61)
Mean age (SD) 17.0 (2.9) 27.0 33.2 23.9 (10.8)
Female % 61.2 21.1 59.1 55.7
Measures of function
Baseline GAF1 functioning (SD) 49.4 (13.3) 47.4 46.3 88.6 (4.82)
Baseline GAF1 symptoms (SD) 45.7 (8.4) 47.6 47.7 87.0 (5.96) 
PAS2 Childhood social functioning mean (SD) 1.47 (1.27) N/A N/A N/A
PAS2 Childhood scholastic performance mean (SD) 2.41 (1.34) N/A N/A N/A
PAS2 Childhood adaptation to school mean (SD) 1.16 (1.10) N/A N/A N/A
PAS2 Early adolescence social functioning mean (SD) 1.70 (1.38) N/A N/A N/A
PAS2 Early adolescence scholastic performance mean (SD) 2.55 (1.37) N/A N/A N/A
PAS2 Early adolescence adaptation to school mean (SD) 1.80 (1.36) N/A N/A N/A
Symptoms and clinical assessments
SCID3 diagnoses
Schizophrenia F20.x 19 22
Bipolar disorder II F31.x 1
Depressive disorder F32.x-33.x 12
Dysthymia F34.x 1
Anxiety disorders F41.x 7
OCD F42.x 1
PTSD F43.1 2
Adjustment disorder F43.2 1
Somatoform disorder F45.x 1
Substance use disorders F10.x-19.x 2
Psychiatric disorder NOS F99.x 1
Psychotic disorder NOS F29.x 3
No diagnosis 17
Mean age of onset for psychosis (SD) N/A 25.7 (5.9) 22.6 (11.5)
Mean years duration of illness (SD) N/A 1.3 (0.85) 10.6 (8.5)
AD medication naïve at baseline % 100 36.8 22.7
DDD mean (SD) N/A 1.8(0.6) 1.4 (0.7)
PANSS4 positive mean (SD) N/A 19.8 (3.7) 21.3 (4.0)
PANSS4 negative mean (SD) N/A 21.1 (6.2) 18.0 (6.5)
PANSS4 general mean (SD) N/A 39.1 (7.8) 38.9 (8.4)
SIPS5 positive mean (SD) 10.7 (3.3) N/A N/A
SIPS5 negative mean (SD) 11.5 (6.1) N/A N/A
SIPS5 general mean (SD) 8.9 (3.6) N/A N/A
Cognitive composites z-score group means (SD)
Speed of processing6 −0.78 (0.89) −0.97 (1.41) −1.80 (1.13)
Working memory7 −0.51 (0.82) −0.18 (1.08) −1.72 (1.66)
Verbal learning, reasoning and problem solving8 −0.50 (0.65) −0.59 (0.78) −0.37 (1.12)
Visual problem solving9 −0.12 (1.18) −0.43 (1.17) −0.40 (1.19)
1GAF; Global Assessment of Functioning, 2PAS, Premorbid Adjustment Scale; 3SCID, Structured Clinical Interview for DSM-IV; 4PANSS, Positive and negative symptoms 
scale; 5SIPS, Structured Interview for Prodromal Symptoms; 6Trailmaking A, WAIS coding, CWIT color, and word reading; 7Trailmaking B, WAIS number span and 
letter number sequencing, inhibition, and inhibition and switching conditions from D-KEFS CWIT; 8D-KEFS FAS, WAIS vocabulary, and CVLT; 9WAIS block design and 
WMS spatial span.
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(D-KEFS FAS, WAIS vocabulary, and CVLT), and spatial reasoning 
(WAIS block design and WMS spatial span). The calculated mean 
z-score for the tests comprising each domain formed the score for 
each of these four domains.
ANOVA Group Comparison
Cognitive subscale z-scores were compared between the groups 
using one-way ANOVAs. The four comparison groups were 
UHR participants and two F20 groups, the first comprising 
participants with duration of illness up to 3 years (SZ1) and the 
second group with duration extending 3 years (SZ2), as well 
as healthy controls. Levene’s test was used to check equality 
of variances between groups. Where the F value indicated 
significant between-group differences, post-hoc pairwise t tests 
were performed in order to assess these. The Siddaq correction 
was applied to adjust for multiple comparisons.
Correlational Analysis
We calculated Pearson correlations between the cognitive subscales 
and symptom scores, i.e., SIPS and PANSS scores, respectively, 
for the UHR and F20 groups. We also calculated the correlation 
between cognitive performance and antipsychotics DDD as well as 
duration of illness for the F20 groups.
RESULTS
Demographic variables for all three groups are displayed in 
Table 1. Owing to the young mean age of the UHR and healthy 
control groups (as young as 13, with many still living at home 
and in full-time mandatory education), years of education, 
living status, and employment levels were not compared 
between groups.
Neuropsychological Profile and Between-
Group Differences
A one-way ANOVA of z-scores based on age- and gender-
controlled norms revealed significant differences in cognitive 
performance between groups, with both the schizophrenia and 
UHR groups scoring lower than healthy controls. Between-
group differences were significant for speed of processing [F(3) = 
18.24, p < 0.001], working memory [F(3) = 13.71, p < 0.001), and 
verbal learning, reasoning, and problem solving  [F(3) = 4.94, 
p = 0.003), but not for visual problem solving [F(3) = 1.16, p = 
0.327]. Group cognitive profiles are displayed for comparison 
in Figure 1. The UHR group had significantly lower scores 
than the control group for speed of processing (p < 0.001), 
working memory (p = 0.042), and verbal learning, reasoning, 
and problem solving (p = 0.007). They scored significantly 
better than the longer duration of illness schizophrenia group 
for speed of processing and working memory (both p < 0.001). 
There were no significant differences in performance between 
the UHR group and the recent onset schizophrenia group in any 
domain. For complete results of pairwise comparisons, please 
refer to Table 2.
Correlational Analysis
Working memory performance was correlated with SIPS 
positive symptoms for the UHR group, while PANSS negative 
score was significantly correlated with verbal learning for 
participants with schizophrenia. However, neither of these 
correlations remained significant upon applying a Bonferroni 
correction for multiple comparisons. There were no significant 
correlations between DDD and cognitive domain scores. 
Complete results from correlation analyses are displayed 
in Table 3.
DISCUSSION
UHR subjects performed significantly worse than the healthy 
control group on measures of speed of processing, cognitive 
flexibility, and verbal learning, reasoning, and problem solving. 
This is in line with our hypothesis and confirms cognitive 
impairment as an observable early sign of a potential psychotic 
disorder. The UHR group also outperformed the schizophrenia 
group with duration of illness longer than 3 years on speed 
of processing and working memory. There were notably no 
significant differences in performance between the UHR group 
and the recent onset F20 group. The cognitive performance 
profile of the UHR group fell in between that of the longer 
duration schizophrenia group and that of the healthy controls 
while matching that of the recent onset participants. Our results 
support previous meta-analytic and review findings (26, 47) of 
impaired cognitive performance in UHR groups, with authors 
arguing for this as a measurable potential vulnerability marker 
preceding severe positive symptoms (3). Interestingly, the UHR 
group performance in tests of spatial abilities (WAIS block design 
and WMS spatial span) was almost identical to that of the control 
group. Our findings are similar to those of another recent study 
which found no impairment in visual skills in a clinical high-risk 
FIGURE 1 | Cognitive profiles in UHR and groups with recent onset and 
longer duration schizophrenia. UHR, ultra high risk group; SZ1, group 
with recent onset schizophrenia (< 3); SZ2, group with remote onset 
schizophrenia (> 3 years). Error bars show 95% CI.
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group, as opposed to in all other domains (48). Spatial abilities 
have previously been found to discriminate between UHR 
individuals who convert to psychosis and those who do not (49, 
50). Others have found no such link (51, 52), although spatial 
abilities were found to be impaired. One study also found a link 
between spatial span and functional outcome (52), meaning that 
these skills could be important when working to limit functional 
loss in UHR individuals.
We suggest that the unimpaired spatial performance of the 
UHR sample in our study could, in part, be due to the inclusion of 
WAIS block design and WMS spatial span tests, both of which use 
physical test objects. Many studies have mainly used nontactile, 
screen-based tests, such as the delayed response task, rather than 
tests involving physical objects. Screen-based tests are likely to load 
more heavily on the working memory and visuospatial sketchpad 
aspect of spatial skills than do tests supported by physical objects. 
If so, this could indicate that the inclusion of physical objects 
may aid the cognitive functioning of this group. We have been 
unable to find any previous research directly comparing these two 
aspects of visuospatial functioning in UHR groups.
SZ1 group performance equaled that of the UHR participants. 
This was surprising, as we were expecting the UHR group to 
outperform SZ1. Significant differences were neither found in 
DDD of medication received nor in baseline antipsychotic naivete 
between the two F20 groups. The similarity to UHR performance 
in the SZ1 group might reflect the findings of other papers, which 
have found few significant performance differences between 
UHR and first-episode psychosis groups while seeing greater 
impairments in more chronic schizophrenia (11). However, we 
hesitate to read too much into these results, as statistical power 
was low given the small subgroup size.
The significant difference in performance between the SZ1 
and SZ2 groups might be explained in several different ways. 
Cognitive performance may decline over the course of illness with 
active psychosis being a neurotoxic state (4), although several 
authors have refuted this idea (12, 28). Another explanation 
may be that better cognitive performance equips people to 
better take advantage of and adhere to any treatment offered, 
thus aiding a quicker recovery. A final explanation which seems 
likely is that the recent onset SZ1 group is genetically diverse. 
It plausibly includes people likely to develop both chronic and 
less severe courses of illness, with better cognitive functioning 
as characteristic of those more likely to recover. Ultimately, only 
longitudinal studies, preferably also tracking genetic factors (53), 
may explain this pattern.
Our results lend support to previous findings that speed of 
processing, working memory, and verbal ability show particular 
impairment studies in both UHR and psychotic disorder groups 
(4). Tasks requiring speed and cognitive flexibility in manipulating 
information appear to present difficulties for both UHR and 
schizophrenia groups. Previous functional MRI studies have found 
changes in major associative fiber tracts/functional connectivity in 
UHR groups (54). DTI studies have found reductions in fractional 
anisotropy as well as increased diffusivity (55) in the UHR 
TABLE 2 | Cognitive domains z-score comparisons between UHR, schizophrenia, and control groups.
Cognitive domain F (sig) p (UHR vs. 
SCZ1)
p (UHR vs. 
SCZ2)
p (UHR vs.  
CTR)
p (SCZ1 vs. 
SCZ2)
p (SCZ1 vs.  
CTR)
p (SCZ2 vs. 
CTR)
Speed of processing1 18.24 (<0.001) 0.981 <0.001** <0.001** 0.080 0.002* <0.001**
Working memory2 13.71 (<0.001) 0.770 <0.001** 0.042* <0.001** 0.995 <0.001**
Verbal learning, reasoning, 
and problem solving3
4.944 (0.003) 0.998 0.998 0.007** 0.022 0.027* 0.303
Visual problem solving4 1.27 (0.327) 0.840 0.890 0.998 1.000 0.587 0.652
*p < 0.05, two-tailed. **p < 0.001, two-tailed UHR, ultra high-risk group; SCZ1, recent onset schizophrenia group; SCZ2, longer duration schizophrenia group; CTR, control group.
1 Trailmaking A, WAIS coding, CWIT color, and word reading; 2 Trailmaking B, WAIS number span and letter number sequencing, inhibition, and inhibition and switching conditions 
from D-KEFS CWIT; 3 D-KEFS FAS, WAIS vocabulary and CVLT; 4 WAIS block design and WMS spatial span.
TABLE 3 | Correlations between cognitive domains and clinical variables.
Speed of processing3 Pearson 
correlation (p)
Working memory4 Pearson 
correlation (p)
Visual problem solving5 
Pearson correlation (p)
Verbal learning, reasoning 
and problem solving6
Pearson correlation (p)
UHR participants 
SIPS positive score1 −0.165 (0.278) −0.305 (0.039)* −0.134 (0.374) −0.063 (0.682)
SIPS negative score1 0.141 (0.372) 0.137 (0.383) 0.083 (0.597) −0.025 (0.875)
SIPS general score1 0.095 (0.544) 0.101 (0.514) −0.048 (0.755) 0.175 (0.262)
F20 participants
PANSS positive score2 0.101 (0.594) −0.015 (0.938) 0.086 (0.597) 0.127 (0.434)
PANSS Negative score2 −0.043 (0.820) 0.117 (0.554) −0.260 (0.105) −0.374 (0.017)*
PANSS General score2 −0.086 (0.652) −0.096 (0.626) −0.275 (0.086) −0.192 (0.234)
Antipsycotic_DDD −0.071 (0.743) −0.138 (0.540) −0.123 (0.508) −0.179 (0.336)
*p < 0.05, two-tailed. 1SIPS, Structured Interview for Prodromal Symptoms; 2PANSS, Positive and Negative Symptoms Scale; 3Trailmaking A, WAIS coding, CWIT color, and word 
reading; 4Trailmaking B, WAIS number span and letter number sequencing, inhibition, and inhibition and switching conditions from D-KEFS CWIT; 5D-KEFS FAS, WAIS vocabulary 
and CVLT; 6WAIS block design and WMS spatial span.
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phase, indicating both demyelination and deterioration in the 
axonal membrane. Taken together, these studies suggest reduced 
connectivity in UHR. Our findings of impaired cognitive flexibility 
and speed can be consistent with reduced white matter connectivity, 
perhaps to a lesser extent than in schizophrenia given the higher 
speed of processing of UHR individuals. In line with this, reductions 
in white matter and abnormalities in white matter microstructure 
in prefrontal and temporal lobe areas have been found to be more 
pronounced in schizophrenia than in UHR groups.
Our findings highlight the importance of clinical attention 
to cognitive problems when aiming to alleviate distress in the 
UHR patient group. The cognitive impairment reported by 
our study suggest cognitive domains that should be targeted in 
the UHR groups in, e.g., academic settings. Working memory, 
attention, and speed of processing performance have been found 
to predict over half of the variance over time in school or work 
participation in clinically stable first-episode psychosis (56). A 
UHR treatment approach including focused interventions for 
cognitive deficits, such as psychoeducation, cognitive training, 
and physical exercise (57), may therefore be crucial in preventing 
further functional loss over time. The relationship between social 
and cognitive functioning would also be an interesting topic for 
future research.
Abnormal synaptic pruning in UHR groups (58) might explain 
their impaired speed of processing. Longitudinal research in 
healthy children has found a puberty-related dip in performance 
speed in tasks requiring working memory and decision making, 
linked by authors to normal synaptic proliferation at this stage 
(59). The same authors argue that healthy synaptic pruning 
after puberty ensures the more effective cognitive performance 
seen their young adult comparison sample. Any disturbance to 
this pruning process is likely to underpin cognitive impairment 
in UHR and schizophrenia when compared to healthy adults. 
Future research should investigate any associations between such 
pruning disturbances and not only cognitive impairment but also 
cognitive change and potential growth in UHR groups.
Despite the clinical diversity of the UHR group, the variance 
in performance is much greater in the schizophrenia group. One 
major reason for this is likely that they simply are a more diverse 
group. First of all, variance is to be expected in a group spanning 
all of adolescence in age. Second, the majority of our UHR sample 
will most likely not go on to develop full-blown psychosis. As 
with all cross-sectional UHR studies, our sample thus includes 
a number of false positives. Our results must therefore be 
interpreted with some caution when searching to elucidate the 
trajectory of cognitive changes in the UHR subgroup who go on 
to develop psychotic disorders. However, our findings are still 
able to inform clinical work with UHR groups, as our sample’s 
diversity is representative of the variability inevitably seen in 
these patients.
Another possible contributor to the greater variability in the UHR 
group is that several different trajectories exist within the development of 
cognitive impairment between the stages of UHR to full-blown psychosis. 
It is also possible and likely that different aspects of cognition develop 
differently. As noted by Corigliano et  al. (11), cross-sectional group 
data also mask potential differences between individual trajectories of 
cognitive functioning, where people may both improve or worsen, as well 
as remaining stable. It is also possible that better cognitive performance at 
the UHR stage may ameliorate the course of illness by better absorbing 
any ensuing decrement in cognitive function as well as by improving 
the individual’s ability to make use of any help and treatment offered. 
Worse performance in chronically ill groups might thus imply lower 
baseline functioning rather than an ongoing decline. Last, poor cognitive 
functioning in UHR may, to some degree, independently coexist with 
psychosis-like experiences. This idea is supported by the existence of 
some cognitive deficits in UHR individuals who do not develop psychotic 
disorder (60). Further longitudinal work is required to identify the 
path of each UHR person, to reveal any individual or group patterns of 
change. Our findings indicate that a decrement in cognitive functioning 
is in place and measurable before the appearance of clinically significant 
positive symptoms of psychosis. Cognitive impairment also appears to be 
more severe in participants with established illness. Although our cross-
sectional design precludes us from concluding firmly, this may indicate 
that further cognitive changes take place during the transition from 
prodromal symptoms to full-blown psychosis. Previous work from our 
research group found cognitive improvement during the early treatment 
of a psychotic episode (30). However, the present study reinforces the fact 
that, despite this improvement, the decrement in functioning remains 
in schizophrenia even after the acute phase. Although not every UHR 
participant will develop psychotic disorder, our current findings indicate 
that cognition most likely continues to change between the UHR stage 
and established psychotic disorder, in line with a neurodevelopmental but 
not necessarily uniformly degenerative model of psychosis.
LIMITATIONS AND STRENGTHS
One limitation of this study is that it is cross-sectional, precluding 
anything but speculation about prediction of individual outcomes 
based on baseline findings. However, we hope that future 
longitudinal analyses of data from the POP project will allow us 
to investigate this. Another limitation is the amount of missing 
data, especially from the schizophrenia group. Naturally, more 
complete data would have been preferable, but is often difficult 
to achieve in this patient group for clinical and ethical reasons.
It is possible that some of the difference between the UHR 
and control group might be due to differences in education 
level. It is difficult to compare and control for this due to UHR 
subjects’ young mean age. However, school dropout before the 
end of mandatory schooling at the age of 16 is extremely rare in 
Norway. Matching as to years of education would thus not yield 
much additional information and might even be misleading 
when including both under 18s and adults in the control group. 
The young age of participants also precluded us from adequately 
measuring and comparing social cognition between groups, 
which might have yielded interesting results.
Owing to the criteria for prodromal syndrome including both 
brief psychosis-like experiences and loss of function over time, 
setting an accurate age of onset is a challenge for this group. This is 
especially the case for the genetic risk and deterioration syndrome 
group where it can be difficult to determine an exact starting point 
for this loss of function. It was decided in our research group that we 
were unable to create a reliable “DUP-like” variable for this group, 
although the inclusion of such a variable would have been of interest.
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One of the main strengths of our study is the presence of a control 
group. Given that UHR patients are quite young, validated norms do 
not exist for all cognitive tests. Use of an age-matched control group 
allowed us to create coordinated norms to compare UHR youth to a 
schizophrenia group from a similar geographical area.
We have also attempted to overcome the challenge in 
UHR research that lack of access to health-care services for 
disadvantaged groups restricts recruitment, making the 
sample less representative. Our current project ran as part 
of Norway’s universal public health-care system, aiming to 
reach vulnerable youth across the catchment area. Despite 
the limitation on generalization caused by our relatively 
small sample size, we believe this strengthens our sample’s 
representativeness.
A further strength of our study is its placement within the 
Norwegian public health-care system, allowing us to recruit 
a wide range of UHR youth from a variety of socioeconomic 
backgrounds, without impacting on their opportunity to get 
treatment at the same cost without enrolling in our study. We 
believe that this makes our sample more representative of the 
general Norwegian UHR population.
CONCLUSION
UHR subjects show impaired cognitive functioning in 
comparison with an age-matched healthy control group on 
speed of processing, working memory, and verbal learning, 
reasoning, and problem solving. Interestingly, spatial task 
performance appeared to be relatively unimpaired. UHR 
subjects performed better than a schizophrenia comparison 
group on speed of processing, but not in other measures. These 
findings highlight the importance of monitoring cognitive 
performance even in a prodromal phase of potential illness. 
Often less explored by clinicians than mood or attenuated 
psychotic symptoms, these symptoms may, in part, explain the 
high subjective distress reported by UHR groups, as cognitive 
impairment will impact both academic and social function.
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